Vivasure Medical Limited is a medical device company based in Galway, Ireland, focused on the research, development, and manufacturing of arterial and venous closure devices utilizing its proprietary PerQseal technology. The company specializes in creating polymer implants and delivery systems aimed at facilitating minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, specifically designed to close large arteriotomies during transcatheter procedures like transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical aims to enhance patient outcomes in vascular access procedures through innovative medical solutions.
Private Equity Round in 2021
Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company specializes in developing and commercializing ReActiv8, an implantable neurostimulation system aimed at treating chronic low back pain. This innovative therapy is designed to restore control to the muscles that stabilize the lumbar spine, addressing a significant unmet need in the healthcare market. By collaborating with scientists and clinical experts, Mainstay Medical focuses on delivering effective solutions for patients suffering from debilitating pain, ultimately enhancing their quality of life.
Neurent Medical Limited is a medical device company based in Galway, Ireland, specializing in the development of innovative treatments for rhinitis. Founded in 2015, the company has created a single-use, minimally invasive device designed for ENT surgeons to address both allergic and non-allergic rhinitis. This hand-held, radio-frequency device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization. It employs a microelectrode array to deliver targeted energy, interrupting the autonomic function of the mucosal structures in the nasal cavities. This approach helps reverse the inflammatory cascade, allowing for effective treatment in an office setting while minimizing the complications and costs commonly associated with traditional surgical procedures.
Neuromod Devices Limited is a medical device company based in Dublin, Ireland, established in 2010. It focuses on the research and development of neuromodulation treatments, specifically targeting chronic tinnitus, a condition that affects approximately 10% of adults. The company's flagship product, the mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the nervous system. Neuromod aims to provide effective treatments for underserved patient populations suffering from chronic and debilitating conditions, enabling them to manage their health more effectively. The company has developed and patented its bi-modal neuromodulation technology, which is also being explored for other neurological disorders.
Priothera Ltd is a clinical-stage company focused on developing orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. Founded in 2020 and based in Dublin, Ireland, with an additional location in Saint Louis, France, the company seeks to improve patient outcomes by enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. Its lead product, mocravimod, is designed to reduce the egress of specific T cell subsets from lymphatic tissues, thereby providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects. Through this innovative approach, Priothera aims to deliver significant advancements in the treatment of patients with blood cancers.
Neuromod Devices Limited is a medical device company based in Dublin, Ireland, established in 2010. It focuses on the research and development of neuromodulation treatments, specifically targeting chronic tinnitus, a condition that affects approximately 10% of adults. The company's flagship product, the mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the nervous system. Neuromod aims to provide effective treatments for underserved patient populations suffering from chronic and debilitating conditions, enabling them to manage their health more effectively. The company has developed and patented its bi-modal neuromodulation technology, which is also being explored for other neurological disorders.
Neurent Medical Limited is a medical device company based in Galway, Ireland, specializing in the development of innovative treatments for rhinitis. Founded in 2015, the company has created a single-use, minimally invasive device designed for ENT surgeons to address both allergic and non-allergic rhinitis. This hand-held, radio-frequency device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization. It employs a microelectrode array to deliver targeted energy, interrupting the autonomic function of the mucosal structures in the nasal cavities. This approach helps reverse the inflammatory cascade, allowing for effective treatment in an office setting while minimizing the complications and costs commonly associated with traditional surgical procedures.
Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company specializes in developing and commercializing ReActiv8, an implantable neurostimulation system aimed at treating chronic low back pain. This innovative therapy is designed to restore control to the muscles that stabilize the lumbar spine, addressing a significant unmet need in the healthcare market. By collaborating with scientists and clinical experts, Mainstay Medical focuses on delivering effective solutions for patients suffering from debilitating pain, ultimately enhancing their quality of life.
Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, founded in 2016, that focuses on developing orally available drugs for inflammatory diseases by targeting the inflammasome. The company's innovative approach aims to block inflammasome signals, addressing the underlying causes of inflammation. Inflazome's portfolio includes treatments for a range of conditions, such as orphan diseases like Muckle-Wells syndrome and familial cold autoinflammatory syndrome, as well as chronic inflammatory disorders affecting the central nervous system, including Alzheimer's, Parkinson's, and multiple sclerosis. The company also targets systemic inflammatory diseases like cardiovascular and gastrointestinal issues, and explores applications in oncology and dermatology. Inflazome operates as a subsidiary of Roche Holding AG.
Vivasure Medical Limited is a medical device company based in Galway, Ireland, focused on the research, development, and manufacturing of arterial and venous closure devices utilizing its proprietary PerQseal technology. The company specializes in creating polymer implants and delivery systems aimed at facilitating minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, specifically designed to close large arteriotomies during transcatheter procedures like transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical aims to enhance patient outcomes in vascular access procedures through innovative medical solutions.
Neuromod Devices Limited is a medical device company based in Dublin, Ireland, established in 2010. It focuses on the research and development of neuromodulation treatments, specifically targeting chronic tinnitus, a condition that affects approximately 10% of adults. The company's flagship product, the mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the nervous system. Neuromod aims to provide effective treatments for underserved patient populations suffering from chronic and debilitating conditions, enabling them to manage their health more effectively. The company has developed and patented its bi-modal neuromodulation technology, which is also being explored for other neurological disorders.
Neuravi Limited is a medical device company based in Galway, Ireland, focused on developing clot retrieval devices to restore blood flow in patients who have experienced ischemic strokes caused by arterial blockages in the brain. The company offers the EmboTrap revascularization devices, which are designed for the treatment of acute ischemic strokes and are available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Founded in 2009, Neuravi operates in the emerging neurointerventional device market and collaborates with researchers and clinicians to advance treatment solutions for this serious condition. As of April 2017, Neuravi is a subsidiary of DePuy Ireland Unlimited Company.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Trino is a drug discovery and early drug development company focused on anti-inflammatory therapeutics. The company is developing drug candidates from a novel, proprietary, class of drugs based on indane dimers derived from a Taiwanese fern. Its lead candidate is a potential first-in-class drug for the treatment of inflammatory bowel disease (IBD), which could be used in both ulcerative colitis (UC) and Crohn’s disease (CD). Trino’s drug class also offers promising candidates with a broad anti-inflammatory activity that could be suitable for applications in dermatology, pulmonary and auto-immune disease.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company specializes in developing and commercializing ReActiv8, an implantable neurostimulation system aimed at treating chronic low back pain. This innovative therapy is designed to restore control to the muscles that stabilize the lumbar spine, addressing a significant unmet need in the healthcare market. By collaborating with scientists and clinical experts, Mainstay Medical focuses on delivering effective solutions for patients suffering from debilitating pain, ultimately enhancing their quality of life.
Neuravi Limited is a medical device company based in Galway, Ireland, focused on developing clot retrieval devices to restore blood flow in patients who have experienced ischemic strokes caused by arterial blockages in the brain. The company offers the EmboTrap revascularization devices, which are designed for the treatment of acute ischemic strokes and are available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Founded in 2009, Neuravi operates in the emerging neurointerventional device market and collaborates with researchers and clinicians to advance treatment solutions for this serious condition. As of April 2017, Neuravi is a subsidiary of DePuy Ireland Unlimited Company.
Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.
Genable Technologies Limited is a bio-pharmaceutical company based in Dublin, Ireland, focused on developing gene therapies for autosomal dominant genetic diseases. The company's primary product, RhoNova, targets rhodopsin-linked autosomal dominant retinitis pigmentosa, a progressive genetic condition leading to blindness caused by mutations in the RHO gene. Genable employs a unique approach that utilizes adeno-associated virus (AAV) vectors to deliver RNA interference molecules, effectively suppressing both faulty and normal gene copies while replacing them with a modified gene that produces a normal protein. This method, known as suppression and replacement, addresses the challenge of mutation variability in dominant diseases. Genable Technologies is backed by a strong portfolio of patents in the United States, Europe, and worldwide, reflecting its innovative contributions to the field of gene therapy.
Amarin Corporation plc is a pharmaceutical company dedicated to developing and commercializing therapeutics for cardiovascular diseases in the United States. Its primary product, Vascepa, is a prescription omega-3 fatty acid capsule designed to reduce triglyceride levels in adults with severe hypertriglyceridemia. The company is also conducting research on the REDUCE-IT study, which targets patients with high triglyceride levels who are undergoing statin therapy. Amarin markets its products primarily to wholesalers and specialty pharmacy providers, utilizing a direct sales force. The company has partnered with Mochida Pharmaceutical Co., Ltd. to further develop and commercialize products based on the active ingredient in Vascepa, eicosapentaenoic acid. Founded in 1989 and headquartered in Dublin, Ireland, Amarin has a research and development facility in Mystic, Connecticut, and focuses on lipid science to enhance cardiovascular disease management.
Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Vivasure Medical Limited is a medical device company based in Galway, Ireland, focused on the research, development, and manufacturing of arterial and venous closure devices utilizing its proprietary PerQseal technology. The company specializes in creating polymer implants and delivery systems aimed at facilitating minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, specifically designed to close large arteriotomies during transcatheter procedures like transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical aims to enhance patient outcomes in vascular access procedures through innovative medical solutions.